Alumis stock slides after envudeucitinib misses lupus trial goal
Alumis shares were pacing for a worst day on record after the company said its lupus drug candidate, envudeucitinib, failed to meet the main goal in a mid-stage trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.